Angiotensin II induces angiogenesis in the hypoxic adult mouse heart in vitro through an AT2-B2 receptor pathway

Hypertension

Volumn 49, Issue 5, 2007, Pages 1178-1185

  Munk, Veronica C ^a   De Miguel, Lourdes Sanchez ^a   Petrimpol, Marco ^a   Butz, Nicole ^a   Banfi, Andrea ^a   Eriksson, Urs ^a   Hein, Lutz ^b   Humar, Rok ^a   Battegay, Edouard J ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Angiotensin II; Bradykinin; Heart; Losartan; Nitric oxide

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; BRADYKININ B2 RECEPTOR; LOSARTAN; NITRIC OXIDE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; HYPOXIA; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; ANOXIA; C57BL MOUSE; CORONARY BLOOD VESSEL; DOSE RESPONSE; DRUG EFFECT; METABOLISM; MOUSE MUTANT; PATHOPHYSIOLOGY;

ANGIOTENSIN II; ANIMALS; ANOXIA; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTOR, BRADYKININ B2;

EID: 34247844373     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.106.080242     Document Type: Article

References (42)

1. Li W, Petrimpol M, Molle KD, Hall MN, Battegay EJ, Humar R. Hypoxia-induced endothelial proliferation requires both mTORC1 and mTORC2. Circ Res. 2007;100:79-87.
2. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9:653-660.
3. Fernandez LA, Caride VJ, Twickler J, Galardy RE. Renin-angiotensin and development of collateral circulation after renal ischemia. Am J Physiol. 1982;243:H869-H875.
4. Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens. 2005;23(suppl):S9-S17.
5. Fernandez LA, Twickler J, Mead A. Neovascularization produced by angiotensin II. J Lab Clin Med. 1985;105:141-145.
6. Ozono R, Matsumoto T, Shingu T, Oshima T, Teranishi Y, Kambe M, Matsuura H, Kajiyama G, Wang ZQ, Moore AF, Carey RM. Expression and localization of angiotensin subtype receptor proteins in the hypertensive rat heart. Am J Physiol Regul Integr Comp Physiol. 2000;278:R781-R789.
7. Chiu AT, Herblin WF, McCall DE, Ardecky RJ, Carini DJ, Duncia JV, Pease LJ, Wong PC, Wexler RR, Johnson AL, Timmermans PBMWM. Identification of angiotensin II receptor subtypes. Biochem Biophys Res Commun. 1989;165:196-203.
8. Whitebread S, Mele M, Kamber B, de Gasparo M. Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochem Biophys Res Commun. 1989;163:284-291.
9. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000;52:415-472.
10. Berry C, Touyz R, Dominiczak AF, Webb RC, Johns DG. Angiotensin receptors: signaling, vascular pathophisiology, and interactions with ceramide. Am J Physiol Heart Circ Physiol. 2001;281:H2337-H2365.
11. Henrion D, Kubis N, Levy BI. Physiological and pathophysiological functions of the AT(2) subtype receptor of angiotensin II: from large arteries to the microcirculation. Hypertension. 2001;38:1150-1157.
12. Volpe M, De Paolis P. Angiotensin II AT2 subtype receptors: an emerging target for cardiovascular therapy. Ital Heart J. 2000;1:96-103.
13. Hein L, Barsh GS, Pratt RE, Dzau VJ, Kobilka BK. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature. 1995;377:744-747.
14. Kiefer FN, Munk VC, Humar R, Dieterle T, Landmann L, Battegay EJ. A versatile in vitro assay for investigating angiogenesis of the heart. Exp Cell Res. 2004;300:272-282.
15. Misko TP, Schilling RJ, Salvemini D, Moore WM, Currie MG. A fluorometric assay for the measurement of nitrite in biological samples. Anal Biochem. 1993;214:11-16.
16. Banai S, Shweiki D, Pinson A, Chandra M, Lazarovici G, Keshet E. Upregulation of vascular endothelial growth factor expression induced by myocardial ischemia: implications for coronary angiogenesis. Cardiovasc Res. 1994;28:1176-1179.
17. Siragy HM, Jaffa AA, Margolius HS, Carey RM. Renin-angiotensin system modulates renal bradykinin production. Am J Physiol. 1996;271:R1090- R1095.
18. 2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest. 1997;15:100:264-269.
19. Azadpour M, Lamas GA. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction. Expert Rev Cardiovasc Ther. 2004;2:891-902.
20. Cao Z, Dean R, Wu L, Casley D, Cooper ME. Role of angiotensin receptor subtypes in mesenteric vascular proliferation and hypertrophy. Hypertension. 1999;34:408-414.
21. Walther T, Menrad A, Orzechowski HD, Siemeister G, Paul M, Schirner M. Differential regulation of in vivo angiogenesis by angiotensin II receptors. FASEB J. 2003;17:2061-2067.
22. de Boer RA, Pinto YM, Suurmeijer AJ, Pokharel S, Scholtens E, Humler M, Saavedra JM, Boomsma F, van Gilst WH, van Veldhuisen DJ. Increased expression of cardiac angiotensin II type 1 (AT(1)) receptors decreases myocardial microvessel density after experimental myocardial infarction. Cardiovasc Res. 2003;57:434-442.
23. Sasaki K, Murohara T, Ikeda H, Sugaya T, Shimada T, Shintani S, Imaizumi T. Evidence for the importance of angiotensin II type 1 receptor in ischemia-induced angiogenesis. J Clin Invest. 2002;109:603-611.
24. Silvestre JS, Tamarat R, Senbonmatsu T, Icchicki T, Ebrahimian T, Iglarz M, Besnard S, Duriez M, Inagami T, Levy BI. Antiangiogenic effect of angiotensin II type 2 receptor in ischemia-induced angiogenesis in mice hindlimb. Circ Res. 2002;90:1072-1079.
25. Egami K, Murohara T, Shimada T, Sasaki K, Shintani S, Sugaya T, Ishii M, Akagi T, Ikeda H, Matsuishi T, Imaizumi T. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest. 2003;112:67-75.
26. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med. 2003;9:677-684.
27. Richard DE, Berra E, Pouyssegur J. Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells. J Biol Chem. 2000;275:26765-26771.
28. 2 receptors. Am J Nephrol. 2004;24:415-421.
29. Chen TH, Wang JF, Chan P, Lee HM. Angiotensin II stimulates hypoxia-inducible factor 1alpha accumulation in glomerular mesangial cells. Ann N Y Acad Sci. 2005;1042:286-293.
30. Chassagne C, Eddahibi S, Adamy C, Rideau D, Marotte F, Dubois-Rande JL, Adnot S, Samuel JL, Teiger E. Modulation of angiotensin II receptor expression during development and regression of hypoxic pulmonary hypertension. Am J Respir Cell Mol Biol. 2000;22:323-332.
31. Berguer R, Hottenstein OD, Palen TE, Stewart JM, Jacobson ED. Bradykinin-induced mesenteric vasodilation is mediated by B2-subtype receptors and nitric oxide. Am J Physiol. 1993,264: G492-G496.
32. Hudlicka O, Brown MD, Walter H, Weiss JB, Bate A. Factors involved in capillary growth in the heart. Mol Cell Biochem. 1995;147:57-68.
33. Tsutsumi Y, Matsubara H, Masaki H, Kurihara H, Murasawa S, Takai S, Miyazaki M, Nozawa Y, Ozono R, Nakagawa K, Miwa T, Kawada N, Mori Y, Shibasaki Y, Tanaka Y, Fujiyama S, Koyama Y, Fujiyama A, Takahashi H, Iwasaka T. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest. 1999;104:925-935.
34. Emanueli C, Minasi A, Zacheo A, Chao J, Chao L, Salis MB, Straino S, Tozzi MG, Smith R, Gaspa L, Bianchini G, Stillo F, Capogrossi MC, Madeddu P. Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia. Circulation. 2001;103:125-132.
35. Silvestre JS, Bergaya S, Tamarat R, Duriez M, Boulanger CM, Levy BI. Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway. Circ Res. 2001;89:678-683.
36. 2 and angiotensin 1-7 receptors in the EDRF-dependent vasodilator effect of angiotensin II on the isolated mesenteric vascular bed of the rat. Br J Pharmacol. 2004;141:860-866.
37. Abadir PM, Periasamy A, Carey RM, Siragy HM. Angiotensin II type 2 receptor-bradykinin B2 receptor functional heterodimerization. Hypertension. 2006;48:316-322.
38. 2 receptors in endothelial cells and isolated ischemic rat hearts. J Hypertens. 1993;11(suppl):S234-S235.
39. Kondo T, Kobayashi K, Murohara T. Nitric oxide signaling during myocardial angiogenesis. Mol Cell Biochem. 2004;264:25-34.
40. 2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension. 1998;31:349-355.
41. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
42. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004-1010.